Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 10/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 5/20 | 0.43 |
| ▸ | CSK | P41240 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | ABL2 | P42684 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22084758 | 0.91 | SRC (0.68) | SRCMEN1KMT2AEGFRCSK | |
| SCHEMBL30150807 | 0.82 | SRC (0.80) | SRCMEN1KMT2AEGFRKDR | |
| SCHEMBL22086027 | 0.82 | SRC (0.80) | SRCMEN1KMT2AEGFRKDR | |
| SCHEMBL30150810 | 0.82 | SRC (0.80) | SRCMEN1KMT2AEGFRKDR | |
| SCHEMBL22086363 | 0.80 | SRC (0.65) | SRCMEN1KMT2AEGFRCSK | |
| SCHEMBL30150808 | 0.80 | SRC (0.65) | SRCMEN1KMT2AEGFRCSK | |
| SCHEMBL22086111 | 0.80 | SRC (0.57) | SRCMEN1KMT2AEGFRCSK | |
| SCHEMBL22086067 | 0.79 | SRC (0.78) | SRCMEN1KMT2AEGFRCSK | |
| SCHEMBL22086537 | 0.79 | LMNA (0.51) | SRCMEN1KMT2AEGFRKDR | |
| SCHEMBL22086534 | 0.77 | LMNA (0.50) | SRCMEN1KMT2ALMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055250-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| WO-2020115481-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055250-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K5, MAP4K1 | SRC 739/4885MEN1 1470/4885KMT2A 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.